FDA approves 4-year intrauterine device

Allergan (NYSE:AGN) and women’s health nonprofit Medicines360 said today that the FDA approved a supplemental new drug application to extend the duration of use for Liletta, a levonorgestrel-releasing intrauterine device, for up to four years.

The hormone-releasing device was first approved in February 2015 and it won additional approval in January last year for a single-handed inserter.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves 4-year intrauterine device appeared first on MassDevice.

from MassDevice http://ift.tt/2wBeZ8b